Paradigm Shift in the Treatment of Patients With ACS

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It plans to enroll 250 participants.

Also called NCT02041650

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 250 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02041650
Other papers using this trial's data
  • High endothelial shear stress and stress gradient at plaque erosion persist up to 12 months International journal of cardiology, 2022-06-15 DOI, PubMed 35306029

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02041650. Non-randomized; no masking; primary purpose treatment. Start 2014-08 (registry gives no type); primary completion 2016-04 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Paradigm Shift in the Treatment of Patients With ACS
Condition
Acute Coronary Syndrome
Intervention (Drug)
Ticagrelor
Lead sponsor
Yu Bo (class: other)
Collaborator
Massachusetts General Hospital (class: other)

Record details

Record id
cardio:ct-nct02041650
Content hash
d19c995ad346bc79e7e782294d34d33068f73210268ffe468ebb4b756b0dbe18